Risperidone treatment alters energy metabolism. (A) Ratio of daily intake of the RISP diet (25 mg/kg) over that of the Ctrl diet when both diets were available in the cage for 7 d; n = 9. (B) Body weight of wild-type C57BL/6 mice fed the Ctrl, RISP-25 (25 mg/kg), or RISP-100 (100 mg/kg) diet; n = 5–10; two-way ANOVA; F(20, 220) = 2.71; P < 0.001. (C) Fat pad weight of mice after 16-wk treatment of the Ctrl or RISP diet. n = 9 or 10; F(2, 34) = 409.2; two-way ANOVA; P < 0.001. (D) H&E staining in mice after 16-wk treatment of the Ctrl or RISP diet. Scale bar is 100 µm. (E–H) Plasma levels of insulin (E), leptin (F), triglyceride (G), and NEFA (H) in mice after 16-wk treatment of the Ctrl or RISP diet. n = 9 or 10. (I) Meal size. Left: traces of continuous measurement in metabolic cages; right: summarized daily average (binned into 12-h light and dark phases) before (black) and after (red) the dietary switch; n = 12; two-way ANOVA; F(1, 22) = 7.452; P = 0.012. *, P < 0.05; **, P < 0.01; and ***, P < 0.001. Two-way ANOVA with Sidak’s post hoc tests in A–C and I. Unpaired t test in E–H. All data were verified in at least two independent experiments. C, control; gWAT, gonadal white adipose tissue; iWAT, inguinal white adipose tissue; R, risperidone. Data are presented as mean ± SEM.